Previously infected vaccinees broadly neutralize SARS-CoV-2 variants.

Autor:	Leier HC; Department of Molecular Microbiology & Immunology, Oregon Health & Science University; Portland, OR 97239, United States., Bates TA; Department of Molecular Microbiology & Immunology, Oregon Health & Science University; Portland, OR 97239, United States., Lyski ZL; Department of Molecular Microbiology & Immunology, Oregon Health & Science University; Portland, OR 97239, United States., McBride SK; Department of Molecular Microbiology & Immunology, Oregon Health & Science University; Portland, OR 97239, United States., Lee DX; Department of Molecular Microbiology & Immunology, Oregon Health & Science University; Portland, OR 97239, United States., Coulter FJ; Department of Molecular Microbiology & Immunology, Oregon Health & Science University; Portland, OR 97239, United States., Goodman JR; Medical Scientist Training Program, Oregon Health & Science University; Portland, OR 97239, United States., Lu Z; Department of Molecular Microbiology & Immunology, Oregon Health & Science University; Portland, OR 97239, United States., Curlin ME; Division of Infectious Diseases, Oregon Health & Science University; Portland, OR 97239, United States., Messer WB; Department of Molecular Microbiology & Immunology, Oregon Health & Science University; Portland, OR 97239, United States.; Division of Infectious Diseases, Oregon Health & Science University; Portland, OR 97239, United States., Tafesse FG; Department of Molecular Microbiology & Immunology, Oregon Health & Science University; Portland, OR 97239, United States.
Jazyk:	angličtina
Zdroj:	MedRxiv : the preprint server for health sciences [medRxiv] 2021 Apr 29. Date of Electronic Publication: 2021 Apr 29.
DOI:	10.1101/2021.04.25.21256049
Abstrakt:	We compared the serum neutralizing antibody titers before and after two doses of the BNT162b2 COVID-19 vaccine in ten individuals who recovered from SARS-CoV-2 infection prior to vaccination to 20 individuals with no history of infection, against clinical isolates of B.1.1.7, B.1.351, P.1, and the original SARS-CoV-2 virus. Vaccination boosted pre-existing levels of anti-SARS-CoV-2 spike antibodies 10-fold in previously infected individuals, but not to levels significantly higher than those of uninfected vaccinees. However, neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees against every variant tested: 5.2-fold against B.1.1.7, 6.5-fold against B.1.351, 4.3-fold against P.1, and 3.4-fold against original SARS-CoV-2. Our study indicates that a first-generation COVID-19 vaccine provides broad protection from SARS-CoV-2 variants in individuals with previous infection. Competing Interests: Competing interests Authors declare that they have no competing interests.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu